Select Publications
Journal articles
2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503
,2024, 'Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus', Clinical Endocrinology, 101, pp. 443 - 445, http://dx.doi.org/10.1111/cen.14819
,2024, 'Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2720 - 2728, http://dx.doi.org/10.1210/clinem/dgae268
,2024, 'Approach to the patient with suspected hypotonic polyuria.', J Clin Endocrinol Metab, http://dx.doi.org/10.1210/clinem/dgae565
,2024, 'Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2', Pituitary, 27, pp. 248 - 258, http://dx.doi.org/10.1007/s11102-024-01385-0
,2024, 'Headache in Patients with Sellar Disease: Clinicomorphological Predictors of Headache and the Outcome of Endoscopic Transsphenoidal Surgery', Journal of Neurological Surgery, Part B: Skull Base, 85, pp. 247 - 254, http://dx.doi.org/10.1055/a-2036-0652
,2024, 'Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement (Nature Reviews Endocrinology, (2023), 19, 12, (722-740), 10.1038/s41574-023-00886-5)', Nature Reviews Endocrinology, 20, pp. 62, http://dx.doi.org/10.1038/s41574-023-00916-2
,2023, 'Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement', Nature Reviews Endocrinology, 19, pp. 722 - 740, http://dx.doi.org/10.1038/s41574-023-00886-5
,2023, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group to Consider Renaming Diabetes Insipidus', Hormone Research in Paediatrics, 96, pp. 423 - 425, http://dx.doi.org/10.1159/000527139
,2023, 'Predictors of pituitary tumour behaviour: An analysis from long-Term follow-up in 2 tertiary centres', European Journal of Endocrinology, 189, pp. 106 - 114, http://dx.doi.org/10.1093/ejendo/lvad079
,2023, 'Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question', European journal of endocrinology, 188, http://dx.doi.org/10.1093/ejendo/lvad042
,2023, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus', Journal of Clinical Endocrinology and Metabolism, 108, pp. 1 - 3, http://dx.doi.org/10.1210/clinem/dgac547
,2023, 'Pituitary tumours: molecular and genetic aspects', Journal of Endocrinology, 257, http://dx.doi.org/10.1530/JOE-22-0291
,2023, 'The evolution in pituitary tumour classification: a clinical perspective.', Endocr Oncol, 3, pp. e220079, http://dx.doi.org/10.1530/EO-22-0079
,2022, 'Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.', J Clin Endocrinol Metab, 108, pp. 1 - 3, http://dx.doi.org/10.1210/clinem/dgac547
,2022, 'Changing the name of diabetes insipidus', Pituitary, 25, pp. 777 - 779, http://dx.doi.org/10.1007/s11102-022-01276-2
,2022, 'Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours', Pituitary, 25, pp. 997 - 1003, http://dx.doi.org/10.1007/s11102-022-01284-2
,2022, 'Temozolomide in aggressive pituitary tumours and pituitary carcinomas', Best Practice and Research: Clinical Endocrinology and Metabolism, 36, http://dx.doi.org/10.1016/j.beem.2022.101713
,2022, 'Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus', Endocrine Connections, 11, http://dx.doi.org/10.1530/EC-22-0378
,2022, 'Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.', Eur J Endocrinol, 187, pp. P1 - P3, http://dx.doi.org/10.1530/EJE-22-0751
,2022, 'Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients', European Journal of Endocrinology, 187, pp. 593 - 605, http://dx.doi.org/10.1530/EJE-22-0440
,2022, 'MEN4, the MEN1 Mimicker: A Case Series of Three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations', Journal of Clinical Endocrinology and Metabolism, 107, pp. 2339 - 2349, http://dx.doi.org/10.1210/clinem/dgac162
,2022, 'Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement', European Journal of Endocrinology, 186, pp. 35 - 52, http://dx.doi.org/10.1530/EJE-21-1186
,2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768, http://dx.doi.org/10.1210/clinem/dgab822
,2022, 'Female Representation: Australian Diabetes and Endocrinology Societies', Frontiers in Endocrinology, 13, http://dx.doi.org/10.3389/fendo.2022.842909
,2022, 'Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments', Frontiers in Endocrinology, 13, http://dx.doi.org/10.3389/fendo.2022.868174
,2022, 'Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas', Pituitary, 25, pp. 64 - 73, http://dx.doi.org/10.1007/s11102-021-01170-3
,2022, 'Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus', Archives of Endocrinology and Metabolism, 66, pp. 868 - 870, http://dx.doi.org/10.20945/2359-3997000000528
,2022, 'Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease.', Endocr Oncol, 2, pp. 19 - 31, http://dx.doi.org/10.1530/EO-21-0026
,2021, 'Consensus on diagnosis and management of Cushing's disease: a guideline update', The Lancet Diabetes and Endocrinology, 9, pp. 847 - 875, http://dx.doi.org/10.1016/S2213-8587(21)00235-7
,2021, 'Childhood-onset prolactinomas—Should earlier surgery be considered?', Clinical Endocrinology, 95, pp. 571 - 573, http://dx.doi.org/10.1111/cen.14477
,2021, 'Towards precision medicine for clinically non-functioning pituitary tumours', Clinical Endocrinology, 95, pp. 398 - 409, http://dx.doi.org/10.1111/cen.14472
,2021, 'Assessment of magnetic resonance imaging criteria for the diagnosis of cavernous sinus invasion by pituitary tumors', Journal of Clinical Neuroscience, 90, pp. 262 - 267, http://dx.doi.org/10.1016/j.jocn.2021.06.010
,2021, 'Multidisciplinary Team Care in the Surgical Management of Pituitary Adenoma', Journal of Neurological Surgery, Part B: Skull Base, 82, pp. 295 - 302, http://dx.doi.org/10.1055/s-0039-1700498
,2021, 'Transcription Factor Immunohistochemistry in the Diagnosis of Pituitary Tumors', Journal of the Endocrine Society, 5, pp. A651 - A651, http://dx.doi.org/10.1210/jendso/bvab048.1327
,2021, 'Transcription factor immunohistochemistry in the diagnosis of pituitary tumours', European Journal of Endocrinology, 184, pp. 891 - 901, http://dx.doi.org/10.1530/EJE-20-1273
,2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, 11, pp. 576027, http://dx.doi.org/10.3389/fendo.2020.576027
,2020, 'Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis', Pituitary, 23, pp. 595 - 609, http://dx.doi.org/10.1007/s11102-020-01066-8
,2020, 'Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective', Pituitary, 23, pp. 327 - 337, http://dx.doi.org/10.1007/s11102-020-01059-7
,2020, 'Fatal high-grade skull osteosarcoma 30 years following radiotherapy for Cushing’s disease', Endocrinology, Diabetes and Metabolism Case Reports, 2020, pp. 1 - 7, http://dx.doi.org/10.1530/EDM-20-0062
,2020, 'Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions', Reviews in Endocrine and Metabolic Disorders, 21, pp. 243 - 251, http://dx.doi.org/10.1007/s11154-020-09562-9
,2020, 'Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives', Reviews in Endocrine and Metabolic Disorders, 21, pp. 263 - 276, http://dx.doi.org/10.1007/s11154-020-09551-y
,2020, 'Long-Term Sinonasal Function Following Transnasal Pituitary Surgery: A Comparison of Surgical Approach', American Journal of Rhinology and Allergy, 34, pp. 361 - 368, http://dx.doi.org/10.1177/1945892419896788
,2020, 'Management of endocrine disease: Does gender matter in the management of acromegaly?', European Journal of Endocrinology, 182, pp. R67 - R82, http://dx.doi.org/10.1530/EJE-19-1023
,2020, 'Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature—“are we there yet?”', Cancers, 12, pp. 308, http://dx.doi.org/10.3390/cancers12020308
,2020, 'Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors', Journal of Clinical Endocrinology and Metabolism, 105, http://dx.doi.org/10.1210/clinem/dgz076
,2019, 'Development and validation of a targeted gene sequencing panel for application to disparate cancers', Scientific Reports, 9, pp. 17052, http://dx.doi.org/10.1038/s41598-019-52000-3
,2019, 'Diagnosing Cushing’s disease in the context of chronic kidney disease: A case report and literature review', European Journal of Endocrinology, 181, pp. K29 - K35, http://dx.doi.org/10.1530/EJE-19-0326
,2019, 'Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases', Cold Spring Harbor Molecular Case Studies, 5, pp. a003764, http://dx.doi.org/10.1101/mcs.a003764
,2018, 'A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly', European Journal of Endocrinology, 179, pp. 97 - 108, http://dx.doi.org/10.1530/EJE-18-0138
,